CDC plans to monitor over 30 pathogens in high-risk airports; a surge in ketamine prescriptions raises questions about safety and oversight; changes to come in Affordable Care Act (ACA) enrollment for 2023.
The CDC is set to enhance its traveler-based surveillance program by adding respiratory virus testing, according to Reuters. The expansion will begin at 4 major US airports, with a focus on the upcoming fall and winter seasons, known for the increased circulation of respiratory diseases like influenza and respiratory syncytial virus (RSV). This proactive approach is driven by the CDC's warning of similar or higher hospitalization rates for COVID-19, RSV infections, and flu compared with the previous year, even exceeding prepandemic levels. The collaboration will closely monitor over 30 pathogens through voluntary nasal swabbing and airport wastewater sampling as part of a public-private partnership.
As opioid painkiller prescriptions decline in the United States, ketamine is emerging as a new option for managing hard-to-treat pain and mental health conditions, according to the Associated Press. The surge in ketamine prescriptions, driven by for-profit clinics and telehealth services, is raising concerns due to limited research on its effectiveness and potential safety and abuse risks. While some patients report positive outcomes, others experience adverse effects, including hallucinations and disturbing thoughts, highlighting the need for further study and oversight of ketamine prescribing, experts say.
The open enrollment period for health insurance plans through the Affordable Care Act (ACA) marketplace is underway, offering new features and potential benefits for prospective customers, according to The Hill. The enrollment period runs until January 15, with an important deadline of December 15 for coverage beginning on January 1. Factors such as increased subsidies, ongoing disenrollment from Medicaid, extended document submission timelines, and an automatic reenrollment policy are expected to influence this year's enrollment numbers. Additionally, stronger insurer participation is increasing the options available to consumers, but it may also present challenges in terms of choice complexity. The ACA Navigator program is available to assist consumers in navigating the more crowded marketplace, with increased investments by the Biden administration to support these efforts.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More